Abstract:Tumor prognosis and immunotherapy efficacy coincides with the infiltration ratio and functional status of immune cells in the tumor microenvironment (TME). Signaling lymphocytes activating molecule factors (SLAMFs) has been reported to play a key role in regulating tumor immunity. Herein, using multi cohorts, in vitro and in vivo experiments, we showed that SLAMF9 worsens tumor and suppresses immune therapy responses by remodeling TME. A pan-cancer analysis showed that SLAMF9 had relatively high transcriptional levels within tumor tissues compared with normal tissues across most cancer types. High SLAMF9 expression is associated with poor prognosis and anti-PD-L1 therapy resistance in advanced clear cell renal cell carcinoma cohorts and metastatic urothelial cancer cohorts. SLAMF9 expression was markedly upregulated in anti-CTLA-4-resistant murine B16 melanoma compared with parental tumors. In particular, SLAMF9 expression was generally negatively correlated with CD8+T cell infiltration score in 12159 patients of 40 cancer types even using different immune cell infiltrating algorithms. Although in vitro experiments have shown that SLAMF9 knockdown has almost no effect on the malignant phenotype of tumor cells, subcutaneous melanoma and lung adenocarcinoma with SLAMF9 deficiency grew slowly, which featured with increased infiltration of CD8+T and PD-1+cells. More importantly, SLAMF9-knockdown significantly increases the sensitivity of subcutaneous melanoma to anti-CTLA-4 inhibitor or anti-PD-L1 antibodies and improved the survival benefits of tumor-bearing mice. This work highlights SLAMF9 as a new target in reshaping the tumor immune microenvironment by controlling the functional status of CD+8 T cells and to improve the efficacy of immunotherapy. Citation Format: Tao Fan, Chu Xiao, Ziqin Deng, Wenpeng Cai, He Tian, Liyu Wang, Chunxiang Li, Jie He. SLAMF9 promotes tumor progression and immunotherapy resistance by reshaping the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1371.

SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies

SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy

Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies

Abstract 1371: SLAMF9 promotes tumor progression and immunotherapy resistance by reshaping the tumor microenvironment

A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects

Comprehensive analysis of signaling lymphocyte activation molecule family as a prognostic biomarker and correlation with immune infiltration in clear cell renal cell carcinoma

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies

Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma

SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma

SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors

The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer

SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

Lipid-mediated regulation of the cancer-immune crosstalk

Multifunctional bispecific nanovesicles targeting SLAMF7 trigger potent antitumor immunity